SJStuart Johnson

Stuart Johnson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stuart Johnson has a total of 177 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular epidemiology and clinical differentiation between Clostridioides difficile infection and colonization across three chicago medical centers

    by Andrew M. Skinner, Do Young Kim, Adam Cheknis, Michael Lin, Mary K. Hayden, Nicholas M. Moore, Amanda Harrington, Vera Tesic, Kathleen G. Beavis, Dale N. Gerding, et al.

    In a retrospective cohort study at three Chicago academic medical centers, 22/81 (27.2%) patients with a clinically adjudicated positive C. difficile test result were colonized. Recent antibiotic usage predicted true infection (adjusted odds ratio: 4.38 for infection). Restriction endonuclease analysis(REA) group Y (29.3%) replaced BI (9.3%) as the dominant strain.


  • Open Access

    Clostridioides difficile clinical diagnostic test methods and results are associated with recovery of C. difficile by stool culture

    by Andrew M. Skinner, Alice Y. Guh, Laurica A. Petrella, Susan Sambol, Adam Cheknis, Stuart Johnson, Christopher A. Czaja, Helen Johnston, Elizabeth Basiliere, Robin A. Dhonau, et al.

    Accurate molecular epidemiology relies on recovering Clostridioides difficile from clinical specimens and is essential for informing public health responses, characterizing strains that cause disease, and tracking strain prevalence. We performed a cross-sectional study of the recovery of C. difficile isolates from test-positive stools received January 2020 through December 2022 from the Colorado and Georgia Emerging Infections Program sites. Multivariable logistic regression models determined the adjusted odds ratio (aOR) and 95% confidence intervals (CIs) for factors which may influence C. difficile recovery in specimens that tested positive by either a dedicated or multiplex polymerase chain reaction (PCR) as part of either a reverse testing algorithm (PCR-positive, arbitrated by toxin enzyme immunoassay [EIA]) or a PCR-only testing protocol. Whole-genome sequencing was performed to determine the multilocus sequence types. C. difficile was recovered by culture from 84.3% (1,527/1,811) of all specimens. In specimens tested with a reverse testing algorithm, C. difficile culture recovery was less likely with multiplex versus dedicated PCR (aOR: 0.53; 95% CI: 0.34–0.85) and more likely in toxin EIA-positive versus toxin EIA-negative specimens (aOR: 8.07; 95% CI: 4.10–18.31). Recovery of C. difficile from stool cultures in PCR-only protocol cases was less likely when C. difficile was detected by multiplex PCR (aOR: 0.16; 95% CI: 0.03–0.55). ST1 was associated with toxin EIA-positive specimens, whereas ST2/110 was associated with toxin EIA-negative specimens. These findings can be used to maximize C. difficile surveillance programs, thereby enhancing the ability to generate robust molecular epidemiology data to inform prevention and control efforts. IMPORTANCE: Public health surveillance of Clostridioides difficile is essential for tracking strains, understanding transmission, and informing public health strategies. The foundation of the surveillance is the successful recovery of C. difficile from clinical specimens for molecular typing. This study reveals that the choice of diagnostic test significantly impacts the ability to recover C. difficile by culture. These data reveal that culture recovery was lower from specimens that tested positive by syndromic multiplex polymerase chain reaction (PCR) panels compared to dedicated C. difficile PCR assays. Furthermore, recovery was more than eight times more likely from toxin enzyme immunoassay (EIA)-positive specimens than from toxin EIA-negative specimens, with high-virulence strains, such as PCR-ribotype 027, being associated with toxin EIA-positive results. These findings demonstrate that common diagnostic practices could introduce biases into surveillance data, potentially misrepresenting the true prevalence and epidemiology of clinically important strains. Understanding these factors is crucial for optimizing surveillance programs to generate accurate molecular epidemiologic data.


  • Clostridioides difficile colonization of Twin Patients Recovering From Infant Botulism

    by Jason R. Barash, Susan P. Sambol, Andrew M. Skinner, Stuart Johnson, Dale N. Gerding


  • Open Access

    Clostridioides difficile in Peripartum Women: Review of Outcomes and Treatment

    by Ravina Kullar, Stuart Johnson, Ellie J. C. Goldstein

    Background: Clostridioides difficile infection (CDI) is one of the most common healthcare-associated infections in the United States with increasing rates in younger patients and those in the community. CDI incidence may also be on the rise in peripartum women. Methods: We conducted a literature review to assess the incidence and outcomes of CDI in the peripartum population and review treatment options. Results: Peripartum patients have a high risk of complications and adverse events associated with CDI. Most patients have been treated with vancomycin or metronidazole; however, cases of patients recurring on standard treatment have been described, with patients having successful outcomes with fidaxomicin or fecal microbiota transplantation (FMT). Probiotics have been shown to be safe in peripartum women; however, the role in preventing primary and secondary CDI has not been studied. Conclusions: Peripartum women that develop CDI are at increased risk for complications. Treatment includes vancomycin, metronidazole, or fidaxomicin or FMT for recurrent cases.


  • Open Access

    Clostridioides difficile should be considered a bacterial priority pathogen

    by Wiep Klaas Smits, Kevin W Garey, Thomas V Riley, Yiping W Han, Vincent B Young, John Heritage, Christian John Lillis, Dena Lyras, Maja Rupnik, Stuart Johnson


  • Open Access

    Clostridioides difficile is a bacterial priority pathogen

    by Wiep Klaas Smits, Kevin W. Garey, Thomas V. Riley, Stuart Johnson


  • Open Access

    Enteritis necroticans and Clostridium perfringens type C; Epidemiological and pathological findings over the past 20 years

    by Stuart Johnson, Andrew M. Skinner, Calob Lostutter, Trevor Duke, Horst Posthaus

    Enteritis necroticans (EN) in humans caused by infection with Clostridium perfringens type C, once thought limited to the highlands of Papua New Guinea has been identified sporadically worldwide. Outbreaks still occur among children in low-income countries and isolated cases occur among children and adults in other countries. Here the disease seems to be associated with diabetes mellitus and other risk factors. C. perfringens type C is also an important cause of necrotizing enteritis among animals, particularly pigs. Research into the pathogenesis of this disease has confirmed the central role of beta toxin and its target, the endothelial cell. Unlike most bacterial enteric infections, the primary anatomic location of EN is the proximal small intestine, reasons for which are not completely understood. Ongoing surveillance for C. perfringens type C infection is warranted as well as public health measures of prevention in locations where environmental and food hygiene is poor.


  • Open Access

    Risk of rehospitalization due to Clostridioides difficile infection among hospitalized patients with Clostridioides difficile: a cohort study

    by Emily N. Drwiega, Stuart Johnson, Larry H. Danziger, Andrew M. Skinner

    Background: Reducing rehospitalization has been a primary focus of hospitals and payors. Recurrence of Clostridioides difficile infection (CDI) is common and often results in rehospitalization. Factors that influence rehospitalization for CDI are not well understood.Objective: To determine the risk factors that influence rehospitalization caused by CDI.Design: A retrospective cohort study from January 1, 2018, to December 31, 2018, of patients aged ≥18 who tested positive for C. difficile while hospitalized.Setting: Academic hospital.Methods: The risk of rehospitalization was assessed across exposures during and after the index hospitalization using a Cox proportional hazards model. The primary outcome of this study was 60-day CDI-related rehospitalization.Results: There were 559 hospitalized patients with a positive CD test during the study period, and 408 patients were included for analysis. All-cause rehospitalization was 46.1% within 60 days of the index hospital discharge. Within 60 days of discharge, 68 patients developed CDI, of which 72.5% (49 of 68) were rehospitalized specifically for the management of CDI. The risk of rehospitalization in patients with CDI was higher among patients who were exposed to systemic antibiotics ([adjusted hazard ratio] aHR: 2.78; 95% CI, 1.36–5.64) and lower among patients who had post-discharge follow-up addressing C. difficile (aHR: 0.53; 95% CI, 0.28–0.98).Conclusions: Exposure to systemic antibiotics increased the risk of rehospitalization due to CDI, while post-discharge follow-up decreased the risk of rehospitalization due to CDI. Comprehensive transitions of care for hospitalized patients with C. difficile may reduce the risk of CDI-related rehospitalization.


  • Epidemiology of Clostridioides difficile infection at one hospital 10 years after an outbreak of the epidemic C. difficile strain BI/027: changing strain prevalence, antimicrobial susceptibilities, and patient antibiotic exposures

    by Jeffrey T. Wieczorkiewicz, Andrew M. Skinner, Adam Cheknis, Laurica A. Petrella, Vanessa W. Stevens, Lorinda M. Wright, Dale N. Gerding, Stuart Johnson

    In contrast to the epidemiology 10 years earlier at our hospital when the epidemic restriction endonuclease analysis (REA) group strain BI accounted for 72% of Clostridioides difficile isolates recovered from first-episode C. difficile infection (CDI) cases, BI represented 19% of first-episode CDI isolates in 2013–2015. Two additional REA group strains accounted for 31% of isolates (Y, 16%; DH, 12%). High-level resistance to fluoroquinolones and azithromycin was more common among BI isolates than among DH, Y, and non-BI/DH/Y isolates. Multivariable analysis revealed that BI cases were 2.47 times more likely to be associated with fluoroquinolone exposure compared to non-BI cases (95% confidence interval [CI]: 1.12–5.46). In addition, the odds of developing a CDI after third- or fourth-generation cephalosporin exposure was 2.83 times for DH cases than for non-DH cases (95% CI: 1.06–7.54). Fluoroquinolone use in the hospital decreased from 2005 to 2015 from a peak of 113 to a low of 56 antimicrobial days/1,000 patient days. In contrast, cephalosporin use increased from 42 to 81 antimicrobial days/1,000 patient days. These changes correlated with a decrease in geometric mean MIC for ciprofloxacin (61.03 to 42.65 mg/L, P = 0.02) and an increase in geometric mean MIC for ceftriaxone (40.87 to 86.14 mg/L, P < 0.01) among BI isolates. The BI strain remained resistant to fluoroquinolones, but an overall decrease in fluoroquinolone use and increase in cephalosporin use were associated with a decrease in the prevalence of BI, an increased diversity of C. difficile strain types, and the emergence of strains DH and Y.


  • Open Access

    Management and Outcomes of Patients at a Specialty Clinic for Clostridioides difficile Infection

    by Aaron Hunt, Larry H Danziger, Stuart Johnson, Andrew M Skinner

    Vancomycin and fidaxomicin taper regimens were the most common treatment strategies employed but nearly half of patients (40/83) referred to our Clostridioides difficile infection (CDI) clinic did not require further treatment. The overall 60-day CDI recurrence rate was 16.9% (11/65). CDI management at a dedicated clinic may improve clinical outcomes.